Farmas USA

Eso quiere decir que me tengo que meter en MNKD en estos últimos minutos para ganarle un 10% mañana????

Jejeje

Edito: Que serás culpable sino eh!!!! y de penitencia, nazareno en la del silencio y descalzo.......

Me pregunto como va a quedar este verano lo de "verano veranete las farmas dan por el culete".

Igual tenemos que cambiarlo a "otoño e inverno" ... o a buscar algo que rime  con "todo el año" .... ya veremos ...

Ten FÉ ja,ja ;)

Jajajaja.

Dos mil dieciséis con las farmas el culo pelado tendréis.

No se si vale, el especialista eres tu.

TGTX Pero que bonicas son... Al tic en la alcista de corto (tanto que casi ni me entra la orden!) y martillico bueno :))

Por cierto, menudo autobombo se han dado en la PR del Abstract que presentarán en AACR, ahí chuleando: The recent announcement of the suspension of a number of studies of idelalisib due to toxicity concerns underscores the need for an improved PI3K-delta inhibitor that is not only efficacious, but safe, convenient and tolerable for patients. Many of the adverse events associated with existing PI3K-delta inhibitors such as colitis and hepatic toxicity, and most recently with opportunistic infections, are thought to be related to T-cell immune mediated mechanisms. To date, TGR-1202 has demonstrated what we and many investigators believe to be best-in-class safety and tolerability profile compared to existing PI3K-delta inhibitors. While still early, we are excited about the pre-clinical data that will be presented at AACR and believe it highlights key differences in the impact of PI3k-delta inhibitors on human T-cell subsets, which may begin to potentially explain the differentiated safety profile observed with TGR-1202 to date in the clinic. We look forward to the upcoming poster presentation by the team at Moffitt, and thank them for all their efforts in our ongoing research collaboration

Verano veranee después del invierno te cabe un barco en el culete

¿8 dias? Seguró que ya han opado Nvax a 35😇😇😇😇

Nvax